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Why the Omega-3 Piggy Should Not Go to Market
Abstract
The paper in your April issue by Lai et al. entitled "Generation of cloned transgenic pigs rich in omega-3
fatty acids" (Nat. Biotechnol. 24, 435–436, 2006) perfectly captures the fundamental problem with
American biotech research. That problem is that scientists pursue their research agenda to further
scientific knowledge - all well and good - but when the project succeeds they invent problems for which
their research results can be marketed as a solution. This unreflective move from 'pure science' to
commercialization may end up as biotech's undoing.
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CORRESPONDENCE
This is where the role of reviewers and editors
becomes important.
The GEO database has had mechanisms for
anonymous reviewer access to prepublication
data since 2003. Over the past several years,
authors have occasionally requested curator
comment regarding the level of MIAME
compliance of their submissions, and we
have been happy to offer feedback on areas
that could be improved. GEO staff are
similarly available to support reviewers and
editors by providing tailored inspections of
MIAME compliance of specific submissions
upon request of the journal, as ArrayExpress
proposes to do in their correspondence in
the November issue of Nature Biotechnology6.
If a reviewer determines that insufficient
information has been supplied, the GEO
database is designed such that authors can
quickly respond by updating their records
accordingly.
It has been challenging to find the
optimal balance between submitter effort
and the appropriate level of metadata detail
to request, all within a rapidly evolving
technological and social environment7.
However, the relative simplicity of the
GEO database structure, together with
common-sense curation policies that focus
on gathering germane MIAME elements,
have made it possible for us to develop an
extensive suite of utilities that makes the

volumes of complex data archived at GEO
accessible and easy to use by the research
community at large8. Ultimately, the value
of a database is reflected in how it is used by
the community it serves. In the past month,
GEO received approximately one million
query hits and over 200,000 file transfer
downloads amounting to over 2.5 terabytes
of compressed data. Furthermore, it is clear
that researchers are applying these data to
their own studies, as demonstrated by over
100 recent publications citing data found in
GEO to support or otherwise complement
their own studies9. We view this as testament
that the effort involved in making expression
data public through GEO is fully justified.
Ron Edgar & Tanya Barrett
National Center for Biotechnology Information,
National Library of Medicine, National Institutes
of Health, 45 Center Drive, Bethesda, Maryland
20892-6511, USA.
e-mail: geo@ncbi.nlm.nih.gov
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Why the omega-3 piggy should not
go to market
To the editor:
The paper in your April
issue by Lai et al. entitled
“Generation of cloned
transgenic pigs rich in
omega-3 fatty acids” (Nat.
Biotechnol. 24, 435–436,
2006) perfectly captures
the fundamental problem
with American biotech
research. That problem is
that scientists pursue their
research agenda to further
scientific knowledge—all
well and good—but when
the project succeeds
they invent problems for
which their research results can be marketed
as a solution. This unreflective move from
‘pure science’ to commercialization may end
up as biotech’s undoing.
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The omega-3 pig is
just the latest ‘product’ to
follow this pattern. Recall
the case of cloned cattle.
As science, these projects
had value in adding to
our understanding of
the process of cloning
and the mechanisms
of reproduction. But
the attempt to employ
this technology for a
marketable product has
hit a hurdle. Although
the safety data on milk
and meat from cloned
cattle appear definitive,
the US Food and Drug Administration still
continues to drag its feet and has failed to
lift the moratorium on the release of cloned
products into the food supply—after three

years. Why? In short, because no one wants
to eat them. Of course, it’s a longer story
than that, but if there were either market
demand or a pressing need for this product,
that moratorium would have been lifted long
ago.
The story of the omega-3 pig has a
parallel plot. Early transgenic projects in
pigs demonstrated an important proof of
concept, but creating omega-3–enhanced
pigs seems to come from the “because
we can” school of justification. Even if
the benefits of dietary omega-3 were
incontrovertible (which they’re not)1,
and even if the only sources of omega-3
were animal based (which they aren’t),
the rationale for creating these genetically
modified (GM) pigs is specious at best. Thus,
in their paper, Lai et al. write, “The only
way to enrich the tissues of mammals with
n-3 fatty acids has been dietary provision
of n-3 fatty acids. Thus, the food industry
must feed animals with flaxseed, fish meal or
other marine products. In view of the decline
in marine fish stocks and the potential
contamination of fish products with
mercury and other chemicals, alternative,
land-based dietary sources of n-3 fatty acids
are needed.” What happened to flaxseed?
But you might say of the super-pig, “so
we don’t need them, and few people are
likely to buy them. Why not let market
forces decide the fate of this product postcommercialization?” There are four reasons
why this pig ought not to go to market.
First, the use of transgenic technology
for this application represents the worst
type of ‘research waste’: precious scientific
resources of time, mental energy and
money that could be used to tackle serious
human and environmental threats are being
devoted to a frivolous cause. The list of
devastating problems begging for a scientific
solution include: chronic, genetic and
infectious diseases, famine, food and water
safety, global warming, the destruction of
ecosystems—the list goes on and on. Because
this project was supported by public money,
including several US National Institutes of
Health grants and one from the US National
Cancer Institute, it took funding away from
other projects that could have been more
beneficial.
Second, the one problem we don’t have is
a shortage of omega-3—even if it turns out
to be the nutritional wonder that some tout
it being, which is now in doubt1. Not only is
it found naturally in readily available foods
like walnuts, flaxseed and fish, but it can
be found in supplements and nutritionally
supplemented foods like Smart Balance
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peanut butter, oil and margarine. We
certainly do have a very serious problem of
obesity and nutrition in the United States
(and increasingly elsewhere), but neither
are problems science needs to solve. We
are obese because we eat too much, and
we are unhealthy because we choose to eat
the wrong foods. Offering us GM pork to
provide us with a plentiful nutrient is an
obvious attempt to drum up a need that
justifies the science.
Third, unlike research on peanut butter,
omega-3 pork requires extensive research
on animals. At a time when Americans are
increasingly concerned about the general use
of animals in scientific research, the animal
biotech industry needs to confine its work
to projects necessary for the achievement of
important health, safety or medical goals.
There are surely worthy goals to pursue in
biotech agriculture and medicine, but this
isn’t one of them. The concern about animal
welfare issues is exacerbated in this case by
the widespread unease with conventional
husbandry practices for this species: pig
farming is one of the most highly criticized
areas in the agricultural sector. Let’s adopt
universal humane farming practices for this
intelligent species before we make animal
welfare matters worse for the pig.
Finally, and for many people, most
worrisome, there is something profoundly
amiss in our stampede down the biotech path
for every trivial application AU:OK?. The level

of the change now possible, the speed at which
we can make these dramatic alterations and
the potential consequences for animals, the
environment and ourselves—for the world as
we know it—ought to give us great pause. It
is naive to think that this research, unbridled,
will have only a trivial impact. This latest work
already says a great deal about us, and it isn’t
flattering. One scientist commented about
the potential of the omega-3 pig: “People can
continue to eat their junk food. You won’t
have to change your diet, but you will be
getting what you need”2. We are altering the
genome of an animal to enable consumers
to continue with their self-destructive eating
habits. What does this say about us if that is
reason enough to manipulate sentient life?
Given the significant financial and
scientific resources that will be required
to bring this pig to market, the absence
of any real need for it, let alone a pressing
one, and the stakes involved in our limitless
pursuit of animal biotech, this is one biotech
application that we ought to forego.
Autumn Fiester
University of Pennsylvania, Medical Ethics, 3401
Market St., Suite 320, Philadelphia, Pennsylvania
19104, USA.
e-mail: fiester@mail.med.upenn.edu
1. Hooper, L. et al. Br. Med. J. 332, 752–760 (2006).
2. Kolata, G. Cloned pigs could provide meat that benefits
the heart. New York Times (March 26, 2006). http://
www.nytimes.com/200603/26/health/26cnd-pig.

Maximizing state and federal
spending while minimizing conflicts
To the editor:
An editorial, “BIO ’06
visible from space?,” in
your April issue (Nat.
Biotechnol. 24, 474, 2006)
highlights how individual
states have begun to
take a more active role
in the development
of life science policy.
Collectively, they are
spending billions of
dollars on everything
from infrastructure and
direct research funding to
workforce enhancements
and investment in

commercial spin-offs.
Designed to fill perceived
gaps at the federal level
and enhance economic
competitiveness, many
state policies are having
the intended effect of
accelerating the pace
of scientific discovery
and commercialization.
Others, however, are
having unintended
consequences and are
overly ambitious, placing
undue strain on limited
resources and venturing
into territory best
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managed at the national level.
As alluded to in the editorial, a report
prepared for the Biotechnology Industry
Organization (BIO; Washington, DC) by
Battelle Technology Partnership Practice
and the State Science and Technology
Institute that was released in April1 indicated
that US states are spending billions of
dollars to support bioscience research and
infrastructure, and even smaller states that
have not traditionally invested in developing
their bioscience base are beginning to
do so. At least 40 states have elaborated
strategic plans and a spectrum of policy
initiatives to enhance development of life
sciences initiatives. Most notable among
these initiatives are those supporting stem
cell research; at least six states have directed
funding to this area, primarily to get
around federal bans on such research. The
expectation of such funding is that the state
will ultimately benefit economically from
stem cell–based commercial spin-offs. Other
state initiatives include R&D infrastructure,
direct support for research, access to seed and
venture capital, workforce and educational
development, and creation of specialized
entities to assist with commercialization and
technology transfer.
However commendable these activities, they
are often insufficient for—and in some cases
detrimental to—the formation of a robust
life sciences academic-industrial complex
that both advances healthcare and drives
economic growth. For a start, most states lack
the capacity for long-term planning of basic
research agendas and for execution of complex
peer review and grants management free of
political influences. Most politics are local,
whereas many health and research priorities
are national and global in scope.
Second, the number and dollar volume
of state initiatives is certain to result in
duplication of efforts across states that far
exceeds what might be considered healthy
competition. In the case of stem cell initiatives,
multiple agencies will be providing regional
funds in multiple states for similar projects,
and the basis for differentiation between
efforts, other than size of the funds available,
is not clear. Other initiatives fall prey to a
lack of understanding of the relationship
between federal funding and facilities like
research laboratories and business incubators.
Without long-term funding to fuel research
initiatives, stimulate training of graduate-level
scientists and engineers, and drive demand
for space, a majority of such facilities will be
underutilized. Under what circumstances,
then, is it rational for states to attempt to affect
economic progress through investment in the
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